首页> 外文期刊>PLoS Pathogens >An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model
【24h】

An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model

机译:EBNA3C缺失的爱泼斯坦-巴尔病毒(EBV)突变体导致脐带血人源化小鼠模型中B细胞淋巴瘤的发作延迟

获取原文
           

摘要

EBV causes human B-cell lymphomas and transforms B cells in vitro. EBNA3C, an EBV protein expressed in latently-infected cells, is required for EBV transformation of B cells in vitro. While EBNA3C undoubtedly plays a key role in allowing EBV to successfully infect B cells, many EBV+ lymphomas do not express this protein, suggesting that cellular mutations and/or signaling pathways may obviate the need for EBNA3C in vivo under certain conditions. EBNA3C collaborates with EBNA3A to repress expression of the CDKN2A-encoded tumor suppressors, p16 and p14, and EBNA3C-deleted EBV transforms B cells containing a p16 germline mutation in vitro. Here we have examined the phenotype of an EBNAC-deleted virus (Δ3C EBV) in a cord blood-humanized mouse model (CBH). We found that the Δ3C virus induced fewer lymphomas (occurring with a delayed onset) in comparison to the wild-type (WT) control virus, although a subset (10/26) of Δ3C-infected CBH mice eventually developed invasive diffuse large B cell lymphomas with type III latency. Both WT and Δ3C viruses induced B-cell lymphomas with restricted B-cell populations and heterogeneous T-cell infiltration. In comparison to WT-infected tumors, Δ3C-infected tumors had greatly increased p16 levels, and RNA-seq analysis revealed a decrease in E2F target gene expression. However, we found that Δ3C-infected tumors expressed c-Myc and cyclin E at similar levels compared to WT-infected tumors, allowing cells to at least partially bypass p16-mediated cell cycle inhibition. The anti-apoptotic proteins, BCL2 and IRF4, were expressed in Δ3C-infected tumors, likely helping cells avoid c-Myc-induced apoptosis. Unexpectedly, Δ3C-infected tumors had increased T-cell infiltration, increased expression of T-cell chemokines (CCL5, CCL20 and CCL22) and enhanced type I interferon response in comparison to WT tumors. Together, these results reveal that EBNA3C contributes to, but is not essential for, EBV-induced lymphomagenesis in CBH mice, and suggest potentially important immunologic roles of EBNA3C in vivo.
机译:EBV导致人B细胞淋巴瘤并在体外转化B细胞。 EBNA3C是在潜伏感染细胞中表达的EBV蛋白,是体外B细胞进行EBV转化所必需的。尽管EBNA3C无疑在使EBV成功感染B细胞中起着关键作用,但许多EBV +淋巴瘤并不表达该蛋白,这表明在某些条件下,细胞突变和/或信号传导途径可避免体内对EBNA3C的需要。 EBNA3C与EBNA3A合作抑制CDKN2A编码的肿瘤抑制因子p16和p14的表达,而EBNA3C缺失的EBV在体外转化了含有p16种系突变的B细胞。在这里,我们检查了脐带血人源化小鼠模型(CBH)中EBNAC删除病毒(Δ3CEBV)的表型。我们发现,与野生型(WT)对照病毒相比,Δ3C病毒诱导的淋巴瘤更少(发生延迟),尽管一部分被Δ3C感染的CBH小鼠(10/26)最终形成了浸润性弥漫性大B细胞III型潜伏期淋巴瘤。 WT和Δ3C病毒均诱导B细胞淋巴瘤,其中B细胞数量有限且T细胞浸润不均。与WT感染的肿瘤相比,Δ3C感染的肿瘤的p16水平大大增加,RNA-seq分析显示E2F靶基因表达降低。然而,我们发现与WT感染的肿瘤相比,Δ3C感染的肿瘤表达c-Myc和细胞周期蛋白E的水平与WT感染的肿瘤相似,从而使细胞至少部分绕过了p16介导的细胞周期抑制。抗凋亡蛋白BCL2和IRF4在Δ3C感染的肿瘤中表达,可能有助于细胞避免c-Myc诱导的细胞凋亡。出乎意料的是,与WT肿瘤相比,受Δ3C感染的肿瘤的T细胞浸润增加,T细胞趋化因子(CCL5,CCL20和CCL22)的表达增加,并且I型干扰素应答增强。在一起,这些结果表明EBNA3C有助于EBV诱导的CBH小鼠淋巴瘤形成,但不是必需的,并提示EBNA3C在体内可能具有重要的免疫作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号